Vaccine Strategies for Dengue Fever

44

Hafiza Aiman Humaira[1], Tasawar Iqbal[2*], Iffat Habib[3] and Zeenat Aman[4]

ABSTRACT

Dengue fever, a widespread viral illness transmitted by mosquitoes, is a major global health concern, especially in tropical and subtropical areas. To proactively address the disease, vaccination plans have been created to minimize its effects. Significantly, the live attenuated vaccine Dengvaxia (CYD-TDV) has been recognized as an innovative intervention. This quadrivalent vaccine introduces individuals to less potent strains of all four dengue virus types, triggering an immune reaction without inducing the illness. The main objective of these vaccines is to provide protection against all virus strains at the same time. However, due to the complicated nature of dengue and its antibody-dependent enhancement, caution is needed in the development of vaccines to prevent making the disease worse. Efforts to implement vaccinations against dengue focus on areas with high rates of transmission, customizing the approach to target specific age groups or populations at higher risk of the disease's effects. Current research is working to improve current vaccines and create new ones to address challenges in vaccine effectiveness and adaptability to different geographic and demographic conditions. The changing nature of dengue transmission and the specific factors related to different age groups highlight the need for flexible vaccine strategies. Consistent communication and advancements in science from health authorities are helping to reduce the global impact of dengue fever through successful vaccination programs.

Keyword: Dengue fever; Dengue vaccine; Tetravalent; Live attenuated; Antibody-dependent enhancement (ADE)

CITATION

Humaira HA, Iqbal T, Habib I and Aman Z, 2023. Vaccine strategies for dengue fever. In: Aguilar-Marcelino L, Zafar MA, Abbas RZ and Khan A (eds), Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan, Vol 3: 561-575. https://doi.org/10.47278/book.zoon/2023.124

CHAPTER HISTORY Received: 07-Feb-2023 Revised: 09-May-2023 Accepted: 14-June-2023

[1]Fazaia Ruth Pfau Medical college, Karachi
[2]Institute of Physiology and Pharmacology, University of Agriculture Faisalabad
[3]Institute of Pharmaceutical Sciences University of Veterinary and animal sciences Lahore
[4]Department of Pharmacognosy, Faculty of Pharmacy, The university of Lahore, Lahore, Pakistan
***Corresponding author:** tasawariqbal177@gmail.com

1. INTRODUCTION

Dengue Fever is a viral illness propagated by the bites of Aedes mosquitoes infected with the virus. Dengue Fever is caused by a viral agent known as the Dengue Virus which encompasses four unique serotypes. It constitutes a significant issue in terms of public health across numerous tropical and subtropical territories on a global scale, such as Southeast Asia, Latin America, and the Caribbean (Kok et al. 2022).

The symptoms of Dengue Fever exhibit a broad spectrum of severity, encompassing hyperthermia, cephalalgia, arthralgia, myalgia, dermatosis, emesis, and anorexia. The manifestation of Dengue Hemorrhagic Fever, a grave variant of Dengue Fever, has been documented to have lethal consequences in certain cases (Huang et al. 2020).

At present, Dengue Fever lacks a targeted intervention, rendering vector control and personal protection the primary means for managing the disease's propagation. The quest for the creation of efficacious vaccines targeting Dengue Fever is a pivotal subject of scientific investigation, and various vaccine prototypes have been formulated and assessed through clinical trials (Pinheiro-Michelsen et al. 2020).

2. PUBLIC HEALTH INFLUENCE

Dengue Fever is a considerable health concern of utmost public importance, with the approximate occurrence of 400 million infections across the world annually. The ailment illicit significant morbidity, potentially resulting in lethality in certain cases. The development of a vaccine for the prevention or mitigation of the symptoms of Dengue Fever would constitute a substantial contribution to the field of public health, especially in regions where the disease is endemic and a considerable source of affliction (Ahmad et al. 2022).

3. ECONOMIC LOAD

Dengue Fever poses a significant economic burden, as evidenced by the substantial healthcare expenses incurred and the productivity losses suffered. The provision of a vaccine capable of averting Dengue Fever would alleviate the financial strain of the ailment on individuals, healthcare frameworks, and communities (Nasir et al. 2020).

4. VECTOR CONTROL EXPERIMENTS

The implementation of vector control measures, namely insecticide spraying and environmental management, represent vital tactics in combating the dissemination of Dengue Fever. Nevertheless, the successful implementation and long-term maintenance of such measures can pose a considerable challenge. The implementation of a vaccine that can effectively prevent Dengue Fever would serve as a supplementary approach to complement the existing vector control measures, thereby contributing towards a significant reduction in the overall disease burden associated with this affliction (Gangmei et al. 2023).

5. INFLUENCE ON TOURISM

Dengue Fever poses a significant and pressing concern for travelers visiting regions that are endemic to the virus, particularly in the context of global travel and tourism. The development of a vaccine against Dengue Fever could significantly mitigate the risk of contagion for travelers and curb the propagation of the ailment to regions where its occurrence is not endemic (Azcarate 2020).

6. EPIDEMIOLOGY OF THE DENGUE FEVER

6.1. DENGUE FEVER PREVALENCE AND INCIDENCE

Dengue Fever is a significant concern in tropical and subtropical regions. It endangers public health and is endemic in over 100 countries, with an estimated 390 million annual infections according to WHO. The number of Dengue Fever cases has increased from 2 million annually in the 1990s to over 3 million annually in recent years. Many cases may go unreported or be misdiagnosed. The prevalence of Dengue Fever varies across countries and regions, with high rates in Southeast Asia and Latin America where the Aedes mosquito is widespread. Urbanization and climate change increase disease transmission in impacted areas. Dengue Fever is a significant global health issue in endemic regions. Developing effective Dengue Fever vaccines is crucial to reducing its impact and improving public health in affected communities (Palaniyandi 2021).

7. GEOGRAPHICAL DISTRIBUTION OF THE DENGUE FEVER

Dengue Fever is caused by the Dengue virus and transmitted by Aedes mosquitoes in tropical regions. Dengue Fever is endemic in 100+ countries, with high incidence in Southeast Asia, Western Pacific, Latin America, Africa, and the Middle East. In Dengue-endemic regions, disease distribution varies greatly with some areas having frequent outbreaks and others only sporadic cases. It is limited to areas with Aedes mosquitoes, mainly Southeast Asia and the Western Pacific. We must work on prevention and vaccines in these endemic regions. Non-endemic regions may face outbreaks due to travel trends, requiring equal attention (Palaniyandi et al. 2021).

8. DENGUE FEVER AS A DISEASE BURDEN

Dengue fever is a global health concern with varying severity, including life-threatening conditions such as Dengue Hemorrhagic Fever and Dengue Shock Syndrome. The accurate measurement of dengue fever's disease burden is difficult due to underreporting and misdiagnosis. It's estimated that around 390 million people suffer from the disease every year. Around 96 million cases show symptoms of dengue fever with 20,000 deaths per year, mostly in children under 15 years. Severe forms of Dengue can lead to a 20% fatality rate. The economic impact includes healthcare costs and decreased productivity. Dengue fever outbreaks impact the local economy and healthcare system in endemic areas. Implementing measures to reduce its spread and effective immunization are crucial for community well-being (Wang et al. 2022).

9. GLOBAL HEALTH IMPACT OF DENGUE FEVER

Dengue fever can have secondary effects on global health, including increased demand for healthcare services, which burdens impacted regions. This may lead to a drop in healthcare accessibility and higher death rates for various illnesses. It has significant economic consequences, particularly in endemic regions where it results in lower productivity and higher healthcare costs. Disease outbreaks can lower tourism and hurt the economy, worsening disease-related issues. Containing dengue fever and creating effective immunizations is crucial for global health. Better surveillance can help us understand disease trends and inform public health interventions. Investing in vaccine research can help to prevent and treat the disease (Wang et al. 2020).

10. PATHOGENESIS OF THE DENGUE FEVER

10.1. FOUR SEROTYPES

The dengue virus comprises of four serotypes that exhibit discernible variations of the virus predicated on the particular proteins discovered on its surface. There are four distinct variations of the dengue virus that are characterized as serotypes (Kothai et al. 2020).

10.1.1. DENGUE VIRUS SEROTYPE I

This serotype is predominantly observed in Southeast Asia and the Western Pacific area, with sporadic occurrences in other global regions. It is correlated with a spectrum of mild to moderate disease (Filho et al. 2019).

10.1.2. DENGUE VIRUS SEROTYPE II

This specific serotype has been observed in numerous regions across the globe, spanning Asia, Africa, and the Americas. There is a significant correlation between the aforementioned condition and the manifestation of severe maladies, such as Dengue Hemorrhagic Fever (Trivedi and Chakravarty 2022).

10.1.3. DENGUE VIRUS SEROTYPE III

This serotype has been detected in numerous regions throughout the globe, spanning Asia, Africa, and the Americas. This condition is potentially linked to mild to moderate manifestations, yet possesses the ability to prompt severe afflictions in certain instances (Tahir Ul Qumar et al. 2019).

10.1.4. DENGUE VIRUS SEROTYPE IV

The aforementioned serotype has been detected across various global regions, such as Asia, Africa, and the Americas. This condition is frequently linked with a spectrum of afflictions ranging from moderate to mild; nonetheless, certain instances may result in grave morbidity (Cui et al. 2022).

11. TRANSMISSION OF DENGUE FEVER

Dengue fever is mainly spread by infected mosquitoes, specifically the *Aedes aegypti* and *Aedes albopictus* species. These mosquitoes are active during the day and commonly found in urban and suburban areas. Dengue Fever can be transmitted through blood transfusions, organ transplants, pregnancy, or childbirth. It cannot be spread through direct contact. Dengue Virus patients can spread it through mosquitoes. To prevent transmission, reduce mosquito populations, use insect repellent and protective clothing, and implement surveillance and public health interventions. Vaccination is crucial to prevent virus transmission (Anoopkumar et al. 2021).

12. REPLICATION AND MECHANISMS OF VIRUS ENTRY

The dengue virus enters host cells through receptor-mediated endocytosis, binding to glycoprotein DC-SIGN or other receptors on immune system cells. The virus enters the host cell through endocytosis and replicates. The virus releases RNA into the host cell's cytoplasm. Translation produces a polyprotein

which is cleaved by proteases, resulting in viral proteins. The virus replication cycle is complex and challenging for developing antiviral treatments. Understanding viral entry and replication is vital for developing effective interventions to stop disease spread (Sirisena et al. 2021).

13. IMMUNE RESPONSE HELPS THE DENGUE VIRUS

The immune response mounted against dengue virus is characterized by its intricate nature, which encompasses both innate and adaptive immune responses.

13.1. INNATE IMMUNE RESPONSE

The indigenous immune response represents the initial barrier of protection in opposition to the dengue virus. Upon infection, host cells are stimulated to release a diverse array of signaling molecules, such as cytokines and chemokines, which attract and trigger an immune response from various types of immune cells, including natural killer (NK) cells, macrophages, and dendritic cells. The aforementioned cells possess the ability to eliminate infected cells directly while also facilitating the activation of the adaptive immune response (DelliPonti et al. 2021).

13.2. ADAPTIVE IMMUNE RESPONSE

The adaptive immune response elicited by the dengue virus entails the generation of antibodies as well as the stimulation of T cells. Antibodies that are generated by B cells exhibit specificity and form a complex with corresponding proteins present on the exterior of the virus, referred as antigens. Antibody-antigen interactions serve as a crucial mechanism for neutralizing viruses and averting their ability to infect host cells. T lymphocytes, upon activation by antigen-presenting cells, possess the ability to identify and eradicate infected cells as well as facilitate the generation of antibody molecules (Kamgang et al. 2019).

14. DENGUE FEVER EXISTING VACCINES

14.1. LIVE ATTENUATED VACCINES

Live attenuated vaccines for dengue fever manipulate the virus for replication in human cells but without pathogenicity. This yields a potent and sustained immune response, similar to natural infection, while reducing severe morbidity. The vaccine virus reproduces and generates antigens that trigger an immune response, producing antibodies and activating T-cells. Monitoring and surveillance are crucial for safe and effective dengue fever vaccines (Jones et al. 2021).

14.2. INACTIVATED VACCINES

Inactivated dengue fever vaccines are produced by growing virus in cell culture, then rendering it inactive with heat, chemicals, or radiation. These vaccines use either the entire inactive virus or only parts, like the envelope protein. Although clinical trials have shown promise, none have been officially approved yet. Inactivated vaccines are easier to manufacture and scale as compared to live attenuated vaccines, making them more suitable for use in areas with high disease incidence (Zhu et al. 2023).

14.3. SUBUNIT VACCINES

Dengue fever subunit vaccines use virus constituents, including the envelope protein, which initiates contact with host cells and triggers an immune response. Subunit vaccines are safer than live or inactivated vaccines as these only use certain components or envelope proteins to induce a strong immune response, reducing the risk of adverse reactions. Subunit vaccines may have limited immunogenicity compared to live attenuated vaccines, as they cannot present viral antigens as effectively. Multiple dengue fever subunit vaccines, including recombinant proteins, virus-like particles, and DNA-based vaccines, are in development. Some inoculations show positive results in trials, but are not approved for use. Subunit vaccines are easier and safer to administer to at-risk individuals, such as children and those with weakened immune systems. These also show promise in high-incidence regions where these can be produced on a large scale without losing effectiveness (Meraj and Gries 2022).

14.4. CHIMERIC VACCINES

Chimeric vaccines for dengue fever combine genetic material from multiple viruses to create a hybrid that incorporates key elements of the dengue virus. This approach reduces negative reactions and enhances immune response. However, chimeric vaccines have possible disadvantages, including the risk of the vaccine virus reverting to a stronger form in areas with high virus prevalence. These vaccines are complex and expensive to produce (Nanaware et al. 2021).

14.5. DNA VACCINES

DNA vaccines for dengue fever involve direct injection of genetic material from the virus into cells, which then produce viral antigens and trigger an immune response. DNA vaccines have advantages over traditional vaccine methods. These are easy and affordable to produce, and can be quickly tailored to target specific viruses. DNA vaccination may provide longer immunity with fewer administrations. DNA vaccines for dengue fever, targeting multiple virus serotypes, are being developed. Vaccines show promise in early trials, but more research is needed for safety and effectiveness. DNA-based vaccines may be less effective than traditional methods. DNA vaccines show promise for preventing dengue fever, but more research is needed to make them safer and more effective (Nanaware et al. 2021).

15. VACCINE DEVELOPMENT STRATEGIES

15.1. TARGETS OF THE VACCINE

Vaccine objectives for dengue fever involve viral envelope protein and NS1, which activate immune response mechanisms. Vaccines targeting NS1 protein aim to produce immune response towards the conserved region present in all four dengue virus serotypes. These are usually NS1 subunit vaccines. Other vaccine targets for dengue fever include viral membrane/capsid proteins and host proteins in the immune response (Nakamura et al. 2023).

15.2. PLATFORMS OF THE VACCINE

Various vaccine platforms are currently being developed for dengue fever, with inherent strengths and limitations for each of these. Several vaccine platforms are currently under development (Verdecia et al. 2021).

15.3. TECHNOLOGIES OF THE NOVEL VACCINE

In contemporary times, a plethora of innovative vaccine technologies has surfaced, demonstrating the possibility of enhanced efficacy, safety, and cost-effectiveness of dengue fever vaccines. Several novel vaccine technologies show significant potential (Korkmaz et al. 2021).

15.4. VIRUS-LIKE PARTICLE VACCINES

Virus-like particle vaccines imitate the structural composition of the virus, yet are void of genetic material, thereby rendering them a safer alternative in comparison to live attenuated or inactivated vaccinations. These vaccines can be efficiently synthesized through recombinant DNA technology, providing a high degree of accuracy in modulating both the size and composition of the vaccine particles. Numerous virus-like particle vaccines aimed at the prevention of dengue fever are presently undergoing development (Nooraei et al. 2021).

15.5. mRNA VACCINES

The messenger RNA (mRNA) vaccines entail encoding of genetic material that specifies a definite antigen, subsequently synthesized by the host's cells. mRNA vaccines possess advantageous characteristics such as low cost and simple production procedures, and hold the potential for swift adaptation to newly evolving viral strains. At present, a number of mRNA-based vaccines intended to counteract dengue fever are undergoing preclinical development (Mukhtar et al. 2022).

15.6. NANOPARTICLE VACCINES

Nanoparticle vaccines employ diminutive, self-arranging particles that imitate the configuration of virus in order to provoke an immune system reaction. The development of nanoparticle vaccines enables the possibility of targeting distinct regions of virus, such as the envelope protein, and can be conveniently adapted to address emergent viral strains. There are presently numerous nanoparticle vaccines in progress for the prevention of dengue fever (Nguyen et al. 2021).

15.7. ADJUVANTS CHEMICAL

Adjuvants are chemical entities that are incorporated into vaccines with the purpose of augmenting the immune response. Novel adjuvants are currently in the process of development, which have the potential to augment the potency of vaccines and concomitantly minimize the number of dosing interventions requisite for optimal immunogenicity. Adjuvants have the potential to mitigate the financial burden associated with vaccines by facilitating the usage of lesser quantities. Various adjuvants are presently undergoing an investigation regarding their potential integration with prevailing vaccines for dengue fever (Eusebio et al. 2021).

16. STRATEGIES FOR THE IMMUNIZATION

Various immunization strategies can be employed to mitigate the incidence of dengue fever. There are a number of items that fall into this category.

16.1. IMMUNIZATION ROUTINE

The act of performing standard inoculation protocols entails administering vaccines to individuals residing in regions with established cases of dengue fever, irrespective of their prior exposure to the pathogen. This approach has been developed with the aim of averting the transmission of the virus in the wider community, as well as curtailing the prevailing rate of disease occurrence (Nivarthi et al. 2021).

16.2. TARGETED IMMUNIZATION

The approach of targeted immunization pertains to the administration of vaccinations to individuals who exhibit a heightened susceptibility to contracting acute illnesses, for instance, young children or persons with pre-existing medical ailments, in order to mitigate the risk of life-threatening medical complications. This strategy has been devised with the primary objective of mitigating the morbidity and mortality rates associated with dengue fever (Idris et al.2021).

16.3. TRAVELER IMMUNIZATION

The process of traveler immunization encompasses the administration of vaccines to individuals who are embarking on trips to regions where dengue fever is prevalent. The present strategy has been formulated with the aim of preventing the dissemination of the virus to other geographical regions across the world and curtailing the possibility of virus introduction into non-endemic areas (Idris et al. 2021).

16.4. MASS IMMUNIZATION

Mass immunization entails the administration of vaccines to a considerable number of individuals within a limited timeframe, typically in reaction to an epidemic of dengue fever. The present strategy is stipulated with an aim to curtail the ongoing dissemination of the virus whilst abating the prevalence of the disease cases (Aguiar et al. 2022). Different types of vaccines available against dengue fever are enlisted in Table 1.

17. PRE-CLINICAL AND CLINICAL ASSESSMENT OF DENGUE FEVER VACCINES

17.1. PRE-CLINICAL STUDIES

Prior to testing a vaccine candidate in humans, preclinical studies are conducted. The primary objective of these investigations is to assess the safety and immunogenicity of the vaccine through the use of animal models (Troost and Smit 2020). Preclinical studies generally encompass multiple stages, which include;

17.1.1. IN VITRO STUDIES

In vitro investigations comprise the assessment of the vaccine candidate's potential to elicit an immunological response by conducting tests on cell cultures. The aforementioned experiments can be employed to ascertain the most favorable quantity and composition of the vaccine (Saptawati et al. 2019).

17.1.2. ANIMAL MODEL STUDIES

The procedure of animal model experimentation entails the application of the vaccine candidate on non-human living organisms like mice or primates with the objective of assessing its safety and immunogenic

Table 1: Dengue fever vaccines

Sr. No	Vaccine name	Development stage of vaccine	Type of vaccine
1	Chimeric Yellow Fever- Tetravalent Dengue Vaccine	Licensed	Live Attenuated vaccine
2	*Takeda's Tetravalent Dengue Vaccine*	Licensed	Live Attenuated vaccine
3	Butantan-D Vaccine	Phase – III	Inactivated vaccine
4	Dengvaxia, Qdenga Vaccine	Phase – III	Live Attenuated vaccine
5	MV-D3 Vaccine	Phase – II	Live attenuated
6	DENVax-4 Vaccine	Pre-clinical	Live Attenuated vaccine
7	rDEN4 Delta 30-200, 201	Pre-clinical	Live Attenuated vaccine
8	D2/NS1-M Vaccine	Pre-clinical	Live Attenuated vaccine
9	TV003/TV005 Vaccine	Phase II	Live Attenuated vaccine
10	DENVax-2 Vaccine	Pre-clinical	Live Attenuated vaccine

capacity. The aforementioned investigations may also be employed to deduce the most advantageous course of delivery and regimen for immunization (Kayesh and Tsukiyama-Kohara 2022).

17.1.3. VIRUS TOXICOLOGY STUDIES

The field of toxicology encompasses an appraisal of the safety profile of a vaccine candidate through animal models to ascertain any potential adverse effects. The primary aim of these investigations is to ascertain any potential safety issues prior to administering the vaccine to human subjects (Moquin et al. 2021).

17.1.4. STABILITY STUDIES

Stability assessments comprise the experimental validation of the vaccine candidate's stability across variable parameters, including temperature and humidity conditions. The conduction of these studies holds considerable significance in guaranteeing the caliber and efficacy of the vaccine throughout its duration of preservation and dissemination (Chen et al. 2021).

17.2. PHASE I CLINICAL TRIALS

Phase I trials evaluate vaccine safety and immune response in humans. Phase I trials involve a small group of healthy subjects observed for negative responses to the vaccine (Alagarasu et al. 2021).

17.2.1. POTENTIAL EFFICACY SIGNALS IDENTIFICATION

The safety and immunogenicity of a given intervention. However, investigators may also scrutinize any plausible indications of efficacy. One prospective monitoring approach entails assessing the decrease in disease incidence or severity among vaccinated populations (Zeyaullah et al. 2022).

17.3. PHASE II CLINICAL TRIALS

Phase II clinical trials test vaccine safety, efficacy, and dosage in humans for dengue fever prevention. The objectives of phase II clinical trials include;

17.3.1. FURTHER ASSESSING THE VACCINE SAFETY

Phase II clinical trials are intended to conduct a comprehensive assessment of the safety profile of the vaccine candidate, particularly with regard to rare or critical adverse events that possibly eluded detection in the preliminary.

17.3.2. TO ASSESS THE IMMUNOGENICITY OF VACCINE

The immunogenic potential of a vaccine candidate in a larger and more representative cohort of study participants. One potential method for determining vaccine efficacy is to quantify the concentrations of immunoglobulins and other immunological indicators in the serum of immunized individuals (Waickman et al. 2019).

17.3.3. PROVIDING PRIMARY DATA ON EFFICACY

Phase II clinical trials are purposed to furnish initial insights into the effectiveness of the vaccine candidate for the prevention of dengue fever. This may involve surveillance of the decrease in disease incidence or severity in the population who have received vaccination in comparison.

17.3.4. PURIFYING THE OPTIMAL DOSE AND PROGRAM

Phase II clinical trials encompass the assessment of diverse doses and schedules of the vaccine candidate with the aim of identifying an optimal therapeutic regimen that can exhibit maximal efficacy while concurrently limiting the occurrence of potential adverse effects.

17.4. PHASE III CLINICAL TRIALS

Phase III trials test vaccines on a large scale in people vulnerable to dengue fever to ensure safety, efficacy, and immunogenicity for regulatory approval. The objectives of phase III clinical trials include;

17.4.1. ASSESSING THE SAFETY OF VACCINE

Phase III clinical trials are specifically structured to appraise the safety of prospective vaccine by enrolling a substantial number of individuals within diverse population groups. The process entails vigilance in the surveillance of potential untoward occurrences or adverse reactions linked to the vaccination (Torres-Flores et al. 2020).

17.4.2. MEASURING THE EFFICACY OF VACCINE

The effectiveness of the vaccine candidate for the prevention of dengue fever. This entails the surveillance of any decrease in the frequency or severity of the illness in immunized individuals when compared to those who have not been vaccinated.

17.4.3. APPROVING THE IMMUNOGENICITY OF VACCINE

The confirmation of the immunogenicity of vaccine candidate by administering the investigational product to a vast population of human subjects. The assessment encompasses quantifying the concentrations of antibodies and other immunological indicators present in the peripheral blood of recipients who have been immunized.

17.4.4. CALCULATING THE LONG-TERM SAFETY AND EFFICACY OF VACCINE

Phase III clinical trials may additionally comprise prolonged observation of immunized individuals in order to assess the consistency of their immune response, as well as to oversee the occurrence of exceptional or belated adverse events linked to the vaccination (Torres-Flores et al. 2022).

18. EXPERIMENTS AND LIMITATIONS IN EMERGING DENGUE FEVER VACCINES

18.1. HETEROLOGOUS IMMUNITY AGAINST DENGUE VIRUS

Heterologous immunity recognizes antigens similar to prior exposure. In dengue fever, it impacts the response to different virus serotypes. When infected with dengue virus, the immune system creates specific antibodies to neutralize that serotype. However, antibodies can cross-react with other serotypes of virus, causing a problem with heterologous immunity. Cross-reactive antibodies from previous infections may worsen dengue virus infection, known as antibody-dependent enhancement (ADE), which complicates dengue fever vaccine development. ADE happens when antibodies in infected person's blood can't fully neutralize a different serotype of virus. They may aid virus entry and impact vaccine development for dengue fever. Vaccine must generate immune response to all 4 dengue virus serotypes, with low risk of ADE (Balz et al. 2020).

18.2. PRIVATION THE CONTACTS OF PROTECTION

A key challenge for a dengue fever vaccine is undefined protection measures. The vaccine's ability to trigger an immune response is crucial for its effectiveness. No prevention method currently exists for dengue fever. The immune response to dengue virus involves antibodies and T cells. Notably, protection against one serotype does not guarantee protection against others, hindering dengue fever vaccine evaluation. It's challenging to determine whether a vaccine protects against or enhances immune response for a disease like dengue fever. Researchers are investigating possible protective factors like antibodies, T cells, and genes. More research is needed to confirm and improve protection measurement methods (John et al. 2019).

18.3. CONCERNS OF VACCINE SAFETY

Vaccine safety is critical for dengue fever vaccines. There are risks that need careful consideration. Dengue fever vaccines may cause severe disease due to ADE. Vaccines must be carefully designed and tested to reduce this risk. Dengue fever vaccines may pose safety concerns due to potential adverse events like fever, headache, and injection site reactions reported by some participants in clinical trials. Monitor dengue fever vaccine safety and theoretical harm risk to non-infected individuals. Incomplete protection from the dengue virus vaccine could potentially increase severe disease risk in subsequent infections, but this is yet to be observed in clinical trials (Wilder-Smith et al. 2019).

18.4. DEVELOPED AND DISTRIBUTION EXPERIMENTS

Production of dengue fever vaccine is critical, especially for large-scale distribution to effectively protect against all four serotypes of the virus. Vaccine production is costly and complex, requiring multiple components. Additionally, the cold chain for storage and transport adds further difficulty. Vaccines require refrigeration or freezing to stay stable, but maintaining the cold chain can be difficult. Researchers and manufacturers seek new ways to produce and distribute vaccines; adjuvants may be key to making production cheaper and more scalable. Manufacturers may use drones to deliver vaccines to remote areas (Gaobots et al. 2022).

19. FUTURE GUIDELINES FOR DENGUE FEVER VACCINE IMPROVEMENT

19.1. NOVEL VACCINE APPLICANTS

Multiple novel vaccine candidates for dengue fever are currently undergoing diverse phases of development and clinical experimentation. The aforementioned vaccine attained regulatory approval as the foremost immunization against dengue fever. This vaccine is a live attenuated formula specifically formulated to elicit a protective response against all four serotypes of the virus. Clinical investigations have demonstrated the efficacy of vaccine against severe cases of dengue fever; however, its potential in mitigating milder forms of the disease remains relatively uncertain.

19.2. MODIFIED VACCINES

Custom vaccines adjust to an individual's genetics and pathogen exposure, creating better immunity for non-traditional vaccine recipients. Dengue fever vaccines can be personalized according to immunity or gene tendencies. UCLA is creating a dengue fever vaccine personalized for severe illness by targeting specific virus regions. This method can produce individualized vaccines for illnesses like dengue fever, which may transform vaccination methods with precise remedies. Personalized vaccines face challenges including accurate prediction of immune response and efficient manufacturing (Meganck 2021).

19.3. IMPLEMENTING THE STRATEGIES OF VACCINE

The implementation of efficacious vaccination strategies for the deployment of dengue fever vaccines represents a pivotal element in the prosperous outcome of any immunization initiative.

19.4. TARGET POPULATIONS AT HIGH RISK

Prioritizing to target the populations that are highly susceptible to contracting dengue fever is of utmost importance. This encompasses populations residing in regions that are endemic or currently undergoing an outbreak.

19.5. PARTICIPATE VACCINES INTO ROUTINE VACCINATION PLANS

The incorporation of the dengue fever vaccine within mainstream immunization programs has the potential to enhance its accessibility to all individuals necessitating its administration.

19.6. MAIN PUBLIC EDUCATION AND AWARENESS MOVEMENTS

The implementation of public education and awareness campaigns holds significance in the enhancement of disease awareness, promotion of vaccination benefits, and resolution of any vaccine hesitancy queries.

19.7. MATE WITH LOCAL HEALTHCARE SUPPLIERS

They have the capacity to furnish continual surveillance and assessment pertaining to the efficacy of vaccine.

19.8. CONFIRM ADEQUATE VACCINE SOURCE

The maintenance of an adequate supply of vaccines stands as a crucial determinant of the success of any vaccination program. The aforementioned plan pertains to the enhancement of proficient manufacturing and distribution networks.

19.9. DEPORTMENT POST-LICENSURE INVESTIGATION

It is imperative to carry out post-licensure surveillance of vaccination for the purpose of monitoring both its safety and efficacy. This approach can facilitate the interpretation of unfavorable occurrences and enable the evaluation of the efficacy of vaccine in mitigating the impact of dengue fever.

19.10. COOPERATE WITH INTERNATIONAL ADMINISTRATIONS

The facilitation of partnerships with global entities, including the World Health Organization (WHO), has the capacity to furnish essential assets and specialized knowledge in order to bolster the creation and implementation of a vaccination program (Meganck 2021).

20. CONCLUSION

Dengue fever is a significant public health concern in tropical and subtropical areas. The virus has four serotypes, and infection with one does not provide immunity for the other three. Dengue virus is mostly transmitted by infected mosquitoes, but there are other ways too. A vaccine is hard to develop due to its complex immune response. Various vaccine types have been developed, including live attenuated, inactivated, subunit, chimeric, and DNA vaccines. Dengue fever cases are expected to keep rising due to urbanization, globalization, and climate change. A vaccine could help stop the disease and save lives. Vaccines can ease dengue fever's financial burden by lowering healthcare costs and productivity losses, thus promoting economic reduction. However, creating and executing vaccines for dengue pose significant challenges. Vaccine safety, lack of protection indicators, manufacturing and distribution difficulties, and potential heterologous immunity hazards all need attention. To improve dengue vaccine effectiveness, focus on research, targeted vaccination, and global accessibility. Prioritize vaccine production and dissemination for public health initiatives.

REFERENCES

Aguiar et al., 2022. Mathematical models for dengue fever epidemiology: A 10-year systematic review. Physics of Life Reviews 40: 65-92.

Ahmad Zamzuri MAI et al., 2022. Perceived Risk for Dengue Infection Mediates the Relationship between Attitude and Practice for Dengue Prevention: A Study in Seremban, Malaysia. International Journal of Environmental Research and Public Health 19: 13252.

Alagarasu et al., 2021. Serotype and genotype diversity of dengue viruses circulating in India: a multi-centre retrospective study involving the Virus Research Diagnostic Laboratory Network in 2018. International Journal of Infectious Diseases 111: 242-252.

Anoopkumar et al., 2021. Environmental epidemiology and neurological manifestations of dengue serotypes with special inference on molecular trends, virus detection, and pathogenicity. Environment, Development and Sustainability 23: 11217-11239.

Azcarate, 2020. Stuck with tourism: Space, power, and labor in contemporary Yucatan, University of California Press.

Balz et al., 2020. Virus-induced T cell-mediated heterologous immunity and vaccine development. Frontiers in Immunology 11: 513.
Bigay et al., 2022. Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in Microbiology 13: 932408.
Chen YC et al., 2021. Micafungin inhibits dengue virus infection through the disruption of virus binding, entry, and stability. Pharmaceuticals 14: 338.
Cui et al., 2022. Dengue and dengue virus in Guangdong, China, 1978–2017: epidemiology, seroprevalence, evolution, and policies. Frontiers in Medicine 9: 797674.
DelliPonti et al., 2021. Structural landscape of the complete genomes of dengue virus serotypes and other viral hemorrhagic fevers. BMC Genomics 22: 1-14.
Eusebio et al., 2021. Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discovery Today 26: 2575-2592.
Filho WL et al., 2019. Climate change, health and mosquito-borne diseases: Trends and implications to the pacific region. International Journal of Environmental Research and Public Health 16: 5114.
Gangmei et al., 2023. A Review on Vector Borne Diseases and Various Strategies to Control Mosquito Vectors: Current strategies to control mosquito vectors. Indian Journal of Entomology.
Gaobots et al., 2022. Recent progress on vaccines produced in transgenic plants. Vaccines 10:1861.
Hitakarun et al., 2022. Cell type variability in the incorporation of lipids in the Dengue virus virion. Viruses 14: 2566.
Huang WH et al., 2020. Assessing the risk of dengue severity using demographic information and laboratory test results with machine learning. PLoS Neglected Tropical Diseases 14: 0008960.
Idris et al., 2021. An update on dengue vaccine development, challenges, and future perspectives. Expert Opinion on Drug Discovery 16:47-58.
John et al., Adaptive immune responses to primary and secondary dengue virus infections. Nature Reviews Immunology 19: 218-230.
Jones et al., 2021. Novel control strategies for mosquito-borne diseases. Philosophical Transactions of the Royal Society 376: 20190802.
Kamgang et al., 2019. Risk of dengue in Central Africa: Vector competence studies with Aedesaegypti and Aedesalbopictus (Diptera: Culicidae) populations and dengue 2 virus. PLoS Neglected Tropical Diseases 13: 0007985.
Kayesh MEH and Tsukiyama-Kohara K, 2022. Mammalian animal models for dengue virus infection: A recent overview. Archives of Virology 2022: 1-14.
Kok BH et al., 2022. Dengue virus infection–a review of pathogenesis, vaccines, diagnosis and therapy. Virus Research 2022: 199018.
Korkmaz et al., 2021. Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases. Expert Opinion on Drug Delivery 18: 151-167.
Kothai et al., 2020. Dengue fever: an overview. Dengue Fever.
Meganck, 2021. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nature Medicine 27: 401-410.
Meraj and Gries G, 2022. The Innate and Adaptive Immune System of the Common Bed Bug, Cimexlectularius: Current Knowledge and Research Opportunities. Hemiptera-Recent Updates.
Moquin SA et al., 2021. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Science Translational Medicine 13: 2181.
Mukhtar et al., 2022. Engineering modified mRNA-based vaccine against dengue virus using computational and reverse vaccinology approaches. International Journal of Molecular Sciences 23: 13911.
Nakamura et al., 2023. Idiotope-Driven T-Cell/B-Cell Collaboration-Based T-Cell Epitope Prediction Using B-Cell Receptor Repertoire Sequences in Infectious Diseases. Viruses 15: 1186.
Nanaware et al., 2021. Dengue virus infection: a tale of viral exploitations and host responses. Viruses 13: 1967.
Nasir et al., 2020. The Societal Economic Burden of Dengue and Awareness Impact. Journal of Law & Social Studies 5: 52-68.
Nguyen et al., 2021. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6: 70.

Nivarthi et al., 2021. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nature Communications 12: 1102.

Nooraei et al., 2021. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology 19: 1-27.

Palaniyandi, 2021. Effects of daily weather on Aedes genus (Culicidae: Diptera) arthropod mosquito vectors profusion and dengue epidemics transmission: A systematic review. International Journal of Ecology and Environmental Sciences 3: 171-177.

Palaniyandi et al., 2021. Effects of daily weather on Aedes genus (Culicidae: Diptera) arthropod mosquito vectors profusion and dengue epidemics transmission: A systematic review. International Journal of Ecology and Environmental Sciences 3: 171-177.

Pinheiro-Michelsen et al., 2020. Anti-dengue vaccines: from development to clinical trials. Frontiers in Immunology 11: 1252.

Saptawati L, et al. 2019. In vitro study of eight Indonesian plants extracts as anti-Dengue virus.

Sirisena et al., 2021. Concurrent dengue infections: Epidemiology & clinical implications. The Indian Journal of Medical Research 154: 669.

Tahir UL Qumar et al., 2019. Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus. Scientific reports 9: 1433.

Torres-Flores et al., 2022. Dengue vaccines: An update. BioDrugs 36: 325-336.

Trivedi S and Chakravarty A, 2022. Neurological complications of dengue fever. Current Neurology and Neuroscience Reports 22: 515-529.

Troost B and Smit JM, 2020. Recent advances in antiviral drug development towards dengue virus. Current Opinion in Virology 43: 9-21.

Verdecia et al., 2021. COVID-19 vaccine platforms: Delivering on a promise? Human Vaccines & Immunotherapeutics 17: 2873-2893.

Waickman et al., 2019. Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Frontiers in Immunology 10: 1778.

Wang et al., 2022. Epidemiological characteristics and temporal-spatial analysis of overseas imported dengue fever cases in outbreak provinces of China, 2005–2019. Infectious Diseases of Poverty 11: 1-17.

Wang WH et al., 2020. Dengue hemorrhagic fever–A systemic literature review of current perspectives on pathogenesis, prevention and control. Journal of Microbiology, Immunology and Infection 53: 963-978.

Wilder-Smith et al., 2019. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report. Vaccine 37: 5137-5146.

Zeyaullah et al., 2022. Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach. Vaccines 10: 1940.

Zhu et al., 2023. Virus-host Interactions in Early Japanese Encephalitis Virus Infection. Virus Research 331: 199120.